Study title: A phase I, multi-centre, randomised, parallel group, open-label, single- and repeated-dose studies to evaluate the pharmacokinetic and pharmacodynamic profile of lansoprazole in neonates with clinically-evident GERD
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Digestive System Diseases | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: LANSOPRAZOLE | |||||
| ATC code: A02BC03 | |||||
| Document link: Lansoprazole_c03-042-synopsis.pdf | |||||
| Document date: 2011-10-14 | |||||
| Study number: C03-042 | |||||
| EudraCT number: | |||||
| Scope of study: CLINICAL | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | Y | - | - | - | |